Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM934 in active systemic lupus erythematosus
NCT03951259Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Jul 2019
- Primary completion
- Oct 2023
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sm934 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Renji Hospital. Primary endpoints: Lupus Low Disease Activity Score at 12 weeks, Systemic Lupus Erythematosus Responder Index - 4 at 12 weeks and 1 more. Started Jul 2019; status: completed.
02
Drugs
sm934
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03951259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951259.